Related Experiment Video
Updated: Apr 16, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Metformin in gestational diabetes: An emerging contender
Awadhesh Kumar Singh1, Ritu Singh2
1Consultant Endocrinologist, Department of Endocrinology, G. D Hospital and Diabetes Institute, Kolkata, West Bengal, India ; Chief Endocrinologist, Department of Endocrinology, Sun Valley Diabetes Hospital, Guwahati, Assam, India.
Indian Journal of Endocrinology and Metabolism
|March 3, 2015
Summary
Gestational diabetes mellitus (GDM) treatment is evolving. This review analyzes metformin
Area of Science:
- Obstetrics and Gynecology
- Endocrinology
- Pharmacology
Background:
- Gestational diabetes mellitus (GDM) prevalence is rising globally.
- GDM results from maternal insulin resistance due to placental hormones.
- Current GDM treatment relies on lifestyle changes or insulin.
Purpose of the Study:
- To critically analyze safety and efficacy data of metformin in GDM.
- To review metformin's use in pregnant women with polycystic ovarian disease.
Main Methods:
- Literature review of clinical studies on metformin in pregnancy.
- Analysis of safety and efficacy data compared to insulin.
- Examination of metformin's placental transfer and effects.
Main Results:
- Metformin is an effective insulin sensitizer for type 2 diabetes.
- Concerns exist regarding metformin crossing the placenta in GDM.
- Emerging data suggests comparable safety and efficacy to insulin.
Conclusions:
- Metformin shows potential as a GDM treatment option.
- Further research is needed to confirm its role and safety profile.
- Metformin may offer an alternative for managing GDM and associated conditions.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
01:22Diabetes Mellitus: Type 2 and Gestational
5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
01:20Pathophysiology of Diabetes
4.6K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:06Oral Hypoglycemic Agents: Glinides
995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
909
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
909